Top

Published in:

01-01-2021 | Graft-Versus-Host Disease | Commentary

Microbiome: an emerging new frontier in graft‑versus‑host disease

Authors: Reena Kumari, Senthilnathan Palaniyandi, Ethan Strattan, Gerhard C. Hildebrandt

Published in: Inflammation Research | Issue 1/2021

Excerpt

The field around the microbiome and graft-versus-host disease (GVHD) is rapidly evolving and so is its literature. Therefore, we consider it important to provide an update on our recent review “Microbiome: An Emerging New Frontier in Graft‑Versus‑Host Disease”. …

Nagpal R, Yadav H. Bacterial translocation from the gut to the distant organs: an overview. Ann Nutr Metab. 2017;71(suppl 1):11–6. https://doi.org/10.1159/000479918.CrossRefPubMed

Jenq RR, Ubeda C, Taur Y, Menezes CC, Khanin R, Dudakov JA, et al. Regulation of intestinal inflammation by microbiota following allogeneic bone marrow transplantation. J Exp Med. 2012;209(5):903–11. https://doi.org/10.1084/jem.20112408.CrossRefPubMedPubMedCentral

Jenq RR, Taur Y, Devlin SM, Ponce DM, Goldberg JD, Ahr KF, et al. Intestinal blautia is associated with reduced death from graft-versus-host disease. Biol Blood Marrow Transpl. 2015;21(8):1373–83. https://doi.org/10.1016/j.bbmt.2015.04.016.CrossRef

Tawara I, Liu C, Tamaki H, Toubai T, Sun Y, Evers R, et al. Influence of donor microbiota on the severity of experimental graft-versus-host-disease. Biol Blood Marrow Transpl. 2013;19(1):164–8. https://doi.org/10.1016/j.bbmt.2012.09.001.CrossRef

Holler E, Butzhammer P, Schmid K, Hundsrucker C, Koestler J, Peter K, et al. Metagenomic analysis of the stool microbiome in patients receiving allogeneic stem cell transplantation: loss of diversity is associated with use of systemic antibiotics and more pronounced in gastrointestinal graft-versus-host disease. Biol Blood Marrow Transpl. 2014;20(5):640–5. https://doi.org/10.1016/j.bbmt.2014.01.030.CrossRef

Taur Y, Jenq RR, Perales MA, Littmann ER, Morjaria S, Ling L, et al. The effects of intestinal tract bacterial diversity on mortality following allogeneic hematopoietic stem cell transplantation. Blood. 2014;124(7):1174–82. https://doi.org/10.1182/blood-2014-02-554725.CrossRefPubMedPubMedCentral

Peled JU, Gomes ALC, Devlin SM, Littmann ER, Taur Y, Sung AD, et al. Microbiota as predictor of mortality in allogeneic hematopoietic-cell transplantation. N Engl J Med. 2020;382(9):822–34. https://doi.org/10.1056/NEJMoa1900623.CrossRefPubMedPubMedCentral

van Beurden YH, de Groot PF, van Nood E, Nieuwdorp M, Keller JJ, Goorhuis A. Complications, effectiveness, and long term follow-up of fecal microbiota transfer by nasoduodenal tube for treatment of recurrent Clostridium difficile infection. United Eur Gastroenterol J. 2017;5(6):868–79. https://doi.org/10.1177/2050640616678099.CrossRef

Zhang F, Yeoh YK, Zuo T, Cheng F, Tang W, Cheung K, et al. Fecal microbiota transplantations reconstitute gut fungal and viral microbiota in graft-versus-host disease. Gut. 2019;68(Suppl 1):A92-A. https://doi.org/10.1136/gutjnl-2019-IDDFAbstracts.172.CrossRef

10.

Bowerman KL, Varelias A, Lachner N, Kuns RD, Hill GR, Hugenholtz P. Continuous pre- and post-transplant exposure to a disease-associated gut microbiome promotes hyper-acute graft-versus-host disease in wild-type mice. Gut Microbes. 2020. https://doi.org/10.1080/19490976.2019.1705729.CrossRefPubMedPubMedCentral

11.

Junghanss C, Marr KA, Carter RA, Sandmaier BM, Maris MB, Maloney DG, et al. Incidence and outcome of bacterial and fungal infections following nonmyeloablative compared with myeloablative allogeneic hematopoietic stem cell transplantation: a matched control study. Biol Blood Marrow Transpl. 2002;8(9):512–20.CrossRef

12.

Hulsdunker J, Ottmuller KJ, Neeff HP, Koyama M, Gao Z, Thomas OS, et al. Neutrophils provide cellular communication between ileum and mesenteric lymph nodes at graft-versus-host disease onset. Blood. 2018;131(16):1858–69. https://doi.org/10.1182/blood-2017-10-812891.CrossRefPubMedPubMedCentral

13.

Schwab L, Goroncy L, Palaniyandi S, Gautam S, Triantafyllopoulou A, Mocsai A, et al. Neutrophil granulocytes recruited upon translocation of intestinal bacteria enhance graft-versus-host disease via tissue damage. Nat Med. 2014;20(6):648–54. https://doi.org/10.1038/nm.3517.CrossRefPubMed

14.

Lee SE, Lim JY, Ryu DB, Kim TW, Park SS, Jeon YW, et al. Alteration of the intestinal microbiota by broad-spectrum antibiotic use correlates with the occurrence of intestinal graft-versus-host disease. Biol Blood Marrow Transpl. 2019;25(10):1933–43. https://doi.org/10.1016/j.bbmt.2019.06.001.CrossRef

15.

Mukherjee S, Hanidziar D. More of the gut in the lung: how two microbiomes meet in ARDS. Yale J Biol Med. 2018;91:143–9.PubMedPubMedCentral

16.

Kyo M, Nishioka K, Nakaya T, Kida Y, Tanabe Y, Ohshimo S, et al. Unique patterns of lower respiratory tract microbiota are associated with inflammation and hospital mortality in acute respiratory distress syndrome. Respir Res. 2019;20(1):246. https://doi.org/10.1186/s12931-019-1203-y.CrossRefPubMedPubMedCentral

17.

Harris B, Morjaria SM, Littmann ER, Geyer AI, Stover DE, Barker JN, et al. Gut microbiota predict pulmonary infiltrates after allogeneic hematopoietic cell transplantation. Am J Respir Crit Care Med. 2016;194(4):450–63. https://doi.org/10.1164/rccm.201507-1491OC.CrossRefPubMedPubMedCentral

18.

Han L, Zhang H, Chen S, Zhou L, Li Y, Zhao K, et al. Intestinal microbiota can predict acute graft-versus-host disease following allogeneic hematopoietic stem cell transplantation. Biol Blood Marrow Transpl. 2019;25(10):1944–55. https://doi.org/10.1016/j.bbmt.2019.07.006.CrossRef

19.

Hülsdünker J, Thomas OS, Haring E, Unger S, Gonzalo Núñez N, Tugues S, et al. Immunization against poly-<em>N</em>-acetylglucosamine reduces neutrophil activation and GVHD while sparing microbial diversity. Proc Natl Acad Sci. 2019;116(41):20700–6. https://doi.org/10.1073/pnas.1908549116.CrossRefPubMed

20.

Ingham AC, Kielsen K, Cilieborg MS, Lund O, Holmes S, Aarestrup FM, et al. Specific gut microbiome members are associated with distinct immune markers in pediatric allogeneic hematopoietic stem cell transplantation. Microbiome. 2019;7(1):131. https://doi.org/10.1186/s40168-019-0745-z.CrossRefPubMedPubMedCentral

21.

Peled JU, Devlin SM, Staffas A, Lumish M, Khanin R, Littmann ER, et al. Intestinal microbiota and relapse after hematopoietic-cell transplantation. J Clin Oncol. 2017;35(15):1650–9. https://doi.org/10.1200/jco.2016.70.3348.CrossRefPubMedPubMedCentral

22.

Neil JA, Cadwell K. The intestinal virome and immunity. J Immunol. 2018;201(6):1615–24. https://doi.org/10.4049/jimmunol.1800631.CrossRefPubMedPubMedCentral

23.

Metzger RN, Krug AB, Eisenacher K. Enteric virome sensing-its role in intestinal homeostasis and immunity. Viruses. 2018. https://doi.org/10.3390/v10040146.CrossRefPubMedPubMedCentral

24.

Legoff J, Resche-Rigon M, Bouquet J, Robin M, Naccache SN, Mercier-Delarue S, et al. The eukaryotic gut virome in hematopoietic stem cell transplantation: new clues in enteric graft-versus-host disease. Nat Med. 2017;23(9):1080–5. https://doi.org/10.1038/nm.4380.CrossRefPubMed

25.

Kumari R, Ahuja V, Paul J. Fluctuations in butyrate-producing bacteria in ulcerative colitis patients of North India. World J Gastroenterol. 2013;19(22):3404–14. https://doi.org/10.3748/wjg.v19.i22.3404.CrossRefPubMedPubMedCentral

26.

Kumari RVN, Paul J. Potential contribution of microbiome in neurodegenerative diseases: Alzheimer’s disease. Inflamm Cell Signal. 2017. https://doi.org/10.14800/ics.1595.CrossRef

27.

Seekatz AM, Theriot CM, Rao K, Chang Y-M, Freeman AE, Kao JY, et al. Restoration of short chain fatty acid and bile acid metabolism following fecal microbiota transplantation in patients with recurrent Clostridium difficile infection. Anaerobe. 2018;53:64–73. https://doi.org/10.1016/j.anaerobe.2018.04.001.CrossRefPubMedPubMedCentral

28.

Dubois T, Tremblay YDN, Hamiot A, Martin-Verstraete I, Deschamps J, Monot M, et al. A microbiota-generated bile salt induces biofilm formation in Clostridium difficile. npj Biofilms Microbiomes. 2019;5(1):14. https://doi.org/10.1038/s41522-019-0087-4.CrossRefPubMedPubMedCentral

29.

DeFilipp Z, Hohmann E, Jenq RR, Chen Y-B. Fecal microbiota transplantation: restoring the injured microbiome after allogeneic hematopoietic cell transplantation. Biol Blood Marrow Transplant. 2019;25(1):e17–22. https://doi.org/10.1016/j.bbmt.2018.10.022.CrossRefPubMed

30.

Bluestone H, Kronman MP, Suskind DL. Fecal microbiota transplantation for recurrent Clostridium difficile infections in pediatric hematopoietic stem cell transplant recipients. J Pediatr Infect Dis Soc. 2017;7(1):e6–8. https://doi.org/10.1093/jpids/pix076.CrossRef

31.

Armour CR, Nayfach S, Pollard KS, Sharpton TJ. A metagenomic meta-analysis reveals functional signatures of health and disease in the human gut microbiome. mSystems. 2019;4(4):e00332-e418. https://doi.org/10.1128/mSystems.00332-18.CrossRefPubMedPubMedCentral

32.

The Human Microbiome Project Consortium. Structure, function and diversity of the healthy human microbiome. Nature. 2012;486(7402):207–14. https://doi.org/10.1038/nature11234.CrossRef

33.

Morgan XC, Tickle TL, Sokol H, Gevers D, Devaney KL, Ward DV, et al. Dysfunction of the intestinal microbiome in inflammatory bowel disease and treatment. Genome Biol. 2012;13(9):R79. https://doi.org/10.1186/gb-2012-13-9-r79.CrossRefPubMedPubMedCentral

34.

Choo JM, Kanno T, Zain NM, Leong LE, Abell GC, Keeble JE, et al. Divergent relationships between fecal microbiota and metabolome following distinct antibiotic-induced disruptions. mSphere. 2017. https://doi.org/10.1128/mSphere.00005-17.CrossRefPubMedPubMedCentral

Title: Microbiome: an emerging new frontier in graft‑versus‑host disease
Authors: Reena Kumari
Senthilnathan Palaniyandi
Ethan Strattan
Gerhard C. Hildebrandt
Publication date: 01-01-2021
Publisher: Springer International Publishing
Keywords: Graft-Versus-Host Disease
Respiratory Microbiota
Graft-Versus-Host Disease
Published in: Inflammation Research / Issue 1/2021
Print ISSN: 1023-3830
Electronic ISSN: 1420-908X
DOI: https://doi.org/10.1007/s00011-020-01419-w

Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Pediatric Cardiology Video

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

Cardiopulmonary Comorbidity Video

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Valvular Heart Disease Video

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discuss last year's major advances in heart failure and cardiomyopathies.

ACC 2024 Congress Coverage

Heart Failure Video

Year in Review: Heart failure and cardiomyopathies

Watch now

Watch this official video from ACC.24. Dr. Biykem Bozkurt discuss last year's major advances in heart failure and cardiomyopathies.

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits

STEP AAG HeroTeaserCollection image/© Tarek / Generated with AI / Stock.adobe.com, ACC 2024 Pediatric and Congenital Heart Disease: Year in Review/© 2024 American College of Cardiology, ACC 2024 Pulmonary Vascular Disease: Year in Review/© 2024 American College of Cardiology, ACC 2024 Valvular Heart Disease: Year in Review/© 2024 American College of Cardiology, ACC 2024 HF and Cardiomyopathies: Year in Review/© 2024 American College of Cardiology, Woman out walking/© Seventyfour / stock.adobe.com (symbolic image with model), Woman checking smartwatch /© saltdium / stock.adobe.com (symbolic image with model), Cardiac catheterization/© Damian / stock.adobe.com

At a glance: The STEP trials

Springer Medicine

Excerpt

Please log in to get access to this content

Other articles of this Issue 1/2021

Burn injury induces elevated inflammatory traffic: the role of NF-κB

Impaired salivary SIgA antibodies elicit oral dysbiosis and subsequent induction of alveolar bone loss

PIM1 inhibition attenuated endotoxin-induced acute lung injury through modulating ELK3/ICAM1 axis on pulmonary microvascular endothelial cells

The role of CD8 + T lymphocytes in chronic obstructive pulmonary disease: a systematic review

The efficacy of in vivo administration of Apremilast on mesenchymal stem cells derived from psoriatic patients

Histamine receptors and COVID-19

Highlights from the ACC 2024 Congress

ACC 2024 Congress Coverage